Your email has been successfully added to our mailing list.

×
-0.000505571605447713 -0.000505571605447713 -0.00319851423854728 -0.00350804787453573 -0.00309533635988441 -0.00330169211721 -0.00144449030127941 -0.00371440363186132
Stock impact report

Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? [Yahoo! Finance]

Incyte Corporation (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Company Research Source: Yahoo! Finance
Incyte recently reported encouraging Phase 1 data for its mutant-CALR antibody INCA033989 in myeloproliferative neoplasms and received a U.S. FDA Breakthrough Therapy designation for essential thrombocythemia, while also naming experienced life sciences lawyer Richard Hoffman as Executive Vice President and General Counsel to lead its legal and compliance functions. Show less Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for INCY alerts
Opt-in for
INCY alerts

from News Quantified
Opt-in for
INCY alerts

from News Quantified